The Phase 2 clinical trial SARA-INT was published in the Journal of Cachexia, Sarcopenia and Muscle (JCSM), the primary reference journal for sarcopenia research, marking a world premiere for Biophytis, a clinical-stage biotechnology company that specializes in creating treatments for age-related diseases.
Key BIO101 Attributes from the SARA INT Trail include:
- Promising Efficacy: BIO101 350mg bid demonstrates a clinically meaningful improvement in the 400-meter walk test (400MWT), primary endpoint of the study
- Excellent Safety: At all doses, BIO101 shows a very good safety profile with no Serious Adverse Events (AE) related to the product
- Greater Efficacy in high-risk population: Nominally significant treatment effect versus placebo in the 400MWT gait speed in slow walkers and sarcopenic obesity subpopulations
About BIOPHYTIS
A clinical-stage biotechnology business, Biophytis SA is dedicated on creating medication candidates for age-related illnesses. The company’s lead drug candidate, BIO101 (20-hydroxyecdysone), is a small molecule being developed for respiratory diseases (COVID-19, Phase 2-3 completed), metabolic disorders (obesity, Phase 2 to be started), and muscular diseases (sarcopenia, Phase 3 ready to start, and Duchenne muscular dystrophy, Phase 1-2 to start).
Learn More: Cures of Duchenne (List of All Researches)
